houghtalingbaemo1268.blogspot.com
The Cambridge, Mass.-based biotechnology companyh also announced that its current President and interim CEO Duncanh Higgons has accepted a position with another privatde biotech company and will be leaving the Bate joins Archemixfrom cross-town peer , wherew he served as president and CEO. Bate held senior executive positiones atMillennium Pharmaceuticals, also of and Biogen, now (Nasdaq: BIIB). He is a founding partnet of JSB Partners, an investment banking and advisorh firm focused on thebiopharmaceuticaol industry. Bate serves on the board at Mass.-based and Cambridge-based AVEO Pharmaceuticals Inc.
He graduated from Williames College and The Wharton Schoolk of Business at the Universityof Pennsylvania. Archemix is focused on discovering, developing and commercializingaptamefr therapeutics. Aptamers bind proteijn targets and may have applications in treatinyg a broad array of The company has partnershipswith (NYSE: Merck Serono, (NYSE: PFE), Takeda, and (NYSE: LLY).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment